Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis

Acute kidney injury (AKI) increases early mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients and may accelerate chronic kidney disease (CKD) development. We analyzed prospective variables related to AKI and CKD in 422 allo-HCT recipients to establish risk factors of severe a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone marrow transplantation (Basingstoke) 2020-07, Vol.55 (7), p.1264-1271
Hauptverfasser: Gutiérrez-García, Gonzalo, Villarreal, Jesús, Garrote, Marta, Rovira, Montserrat, Blasco, Miquel, Suárez-Lledó, María, Rodríguez-Lobato, Luis Gerardo, Charry, Paola, Rosiñol, Laura, Marín, Pedro, Pedraza, Alexandra, Solano, María Teresa, Ramos, Carla, de Llobet, Noemí, Lozano, Miquel, Cid, Joan, Martínez, Carmen, Poch, Esteban, Carreras, Enric, Urbano-Ispizua, Álvaro, Fernández-Avilés, Francesc, Pereira, A., Quintana, Luis F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Acute kidney injury (AKI) increases early mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients and may accelerate chronic kidney disease (CKD) development. We analyzed prospective variables related to AKI and CKD in 422 allo-HCT recipients to establish risk factors of severe acute renal failure and CKD. Renal function and creatinine were periodically assessed from baseline till the last follow-up. Sixty-three patients (14%) developed severe AKI (AKI-3) at 100 days post transplant and 15% at 12 months. Variables associated with AKI-3 were age above 55 years [hazard ratio (HR): 2.4; p  = 0.019], total body irradiation (TBI) (HR: 1.8; p  = 0.044), high-risk cytomegalovirus reactivation (HR: 1.8; p  = 0.041), and methotrexate as GVHD prophylaxis (HR: 2.1; p  = 0.024). AKI-3 increased the mortality risk (HR: 2.5, 95% confidence interval: 1.9–3.4). The CKD prevalence in 161 living patients was 10.2% at the last follow-up and in most, CKD developed 1 year post HCT, independent of AKI. The CKD at 1 year post HCT was associated with increased mortality (HR: 3.54; p  
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-020-0843-3